Related Experiment Videos
Plasma concentrations of alpha-human atrial natriuretic polypeptide and cyclic GMP in patients with heart disease
Insights
Elevated levels of alpha-human atrial natriuretic polypeptide (i alpha-hANP) and cyclic guanosine monophosphate (cGMP) in heart disease patients correlate with disease severity. These biomarkers reflect increased ANP secretion and circulating ANP levels.
Area of Science:
- Cardiology
- Endocrinology
- Biochemistry
Background:
- Heart disease is associated with complex physiological changes.
- Atrial natriuretic polypeptides (ANPs) play a role in cardiovascular regulation.
- Cyclic guanosine monophosphate (cGMP) is a key second messenger in ANP signaling pathways.
Purpose of the Study:
- To investigate the relationship between plasma levels of i alpha-hANP and cGMP and the severity of heart disease.
- To explore the correlation of these biomarkers with hemodynamic parameters.
- To elucidate the origin and reflection of circulating ANP and cGMP in cardiac patients.
Main Methods:
- Measurement of plasma concentrations of immunoreactive alpha-human atrial natriuretic polypeptide (i alpha-hANP) and cyclic guanosine monophosphate (cGMP) in 70 heart disease patients.
- Correlation analysis with clinical severity and hemodynamic measurements (PCWP, PAP, RAP).
- Comparison of biomarker concentrations in plasma from coronary sinus and pulmonary artery.
Main Results:
- Plasma i alpha-hANP and cGMP concentrations were directly related to heart disease severity.
- Both biomarkers strongly correlated with pulmonary capillary wedge pressure, pulmonary arterial pressure, and right atrial pressure.
- i alpha-hANP levels were significantly higher in coronary sinus plasma compared to pulmonary artery plasma, while cGMP levels were similar.
Conclusions:
- Elevated plasma i alpha-hANP in cardiac patients indicates increased ANP secretion, likely due to elevated atrial pressures.
- Plasma cGMP concentrations serve as a reliable indicator of circulating alpha-hANP levels.
- These findings highlight the diagnostic and prognostic potential of i alpha-hANP and cGMP in heart disease management.
Abstract:
Plasma concentrations of immunoreactive alpha-human atrial natriuretic polypeptide (i alpha-hANP) and cyclic guanosine monophosphate (cGMP) were measured in 70 patients with heart disease. Plasma concentrations of i alpha-hANP were directly related to the severity of heart disease (F = 29.61, p less than 0.001). Plasma concentrations of i alpha-hANP were well correlated with pulmonary capillary wedge pressure (PCWP; r = 0.64, p less than 0.001), mean pulmonary arterial pressure (PAP; r = 0.62, p less than 0.001), and mean right atrial pressure (RAP; r = 0.75, p less than 0.001). Plasma concentrations of cGMP were also directly related to the severity of heart disease (F = 13.61, p less than 0.001) and highly correlated with plasma concentrations of i alpha-hANP (r = 0.73, p less than 0.001). Plasma concentrations of cGMP were also closely correlated with PCWP (r = 0.69, p less than 0.001), mean PAP (r = 0.61, p less than 0.001), and mean RAP (r = 0.60, p less than 0.001). The i alpha-hANP concentrations of plasma samples obtained from the coronary sinus were approximately fourfold higher than those of samples obtained from the pulmonary artery, whereas cGMP concentrations were comparable in plasma samples obtained from either site. Elevation of cGMP concentrations following intravenous infusion of synthetic alpha-hANP was comparable in plasma samples obtained from the coronary sinus and the pulmonary artery. These findings suggest that elevated plasma concentrations of i alpha-hANP in cardiac patients result from an increase in the secretion of ANPs, which is probably accelerated by elevation of right or left atrial pressure, and that plasma concentrations of cGMP reflect circulating levels of alpha-hANP.